The Phase I part of the study will apply to identify dose-limiting toxicities (DLT) and to
define maximum-tolerated dose (MTD) for a new chemoimmunotherapy combination of bendamustine,
ofatumumab, carboplatin, and etoposide in patients with Non Hodgkin's lymphoma whose disease
has progressed or has recurred after prior chemotherapy.
The Phase II part of the study will be a single-arm, open-label study in which all patients
will receive combination bendamustine, ofatumumab, carboplatin and etoposide at the MTD dose
defined in phase I.
This study hopes to identify a life-prolonging therapy for patients with Non-Hodgkin's
Lymphoma whose disease has progressed or has recurred after prior chemotherapy. The
hypothesis is that the proposed combination of chemotherapy is well-tolerated and is
efficacious for the treatment of relapsed/refractory aggressive B cell lymphomas.